Janux Therapeutics, Inc. (NASDAQ:JANX) Given Consensus Recommendation of "Buy" by Brokerages

Key Points

• Janux Therapeutics, Inc. has received a consensus recommendation of "Buy" from thirteen analysts, with an average price target of $86.90.
• Recent institutional investments have significantly increased, with institutions now owning 75.39% of the company's stock, indicating strong confidence in its potential.
• Janux reported a loss of ($0.55) EPS for the latest quarter, missing the consensus estimate, but is actively developing therapies for various cancers.

Shares of Janux Therapeutics, Inc. (NASDAQ:JANX - Get Free Report) have been assigned a consensus recommendation of "Buy" from the thirteen analysts that are covering the firm, Marketbeat.com reports. One research analyst has rated the stock with a hold recommendation, ten have assigned a buy recommendation and two have assigned a strong buy recommendation to the company. The average 12 month price target among analysts that have issued ratings on the stock in the last year is $86.90.

JANX has been the topic of a number of recent analyst reports. Piper Sandler started coverage on Janux Therapeutics in a research report on Monday, August 18th. They set an "overweight" rating and a $42.00 target price on the stock. Raymond James Financial assumed coverage on Janux Therapeutics in a research note on Friday, July 11th. They issued an "outperform" rating and a $65.00 target price for the company.

Institutional Inflows and Outflows

A number of institutional investors have recently modified their holdings of JANX. GF Fund Management CO. LTD. purchased a new stake in shares of Janux Therapeutics in the fourth quarter valued at $59,000. GAMMA Investing LLC raised its holdings in shares of Janux Therapeutics by 1,574.0% in the 1st quarter. GAMMA Investing LLC now owns 1,674 shares of the company's stock worth $45,000 after purchasing an additional 1,574 shares during the period. US Bancorp DE raised its holdings in shares of Janux Therapeutics by 2,402.9% in the 1st quarter. US Bancorp DE now owns 1,727 shares of the company's stock worth $47,000 after purchasing an additional 1,658 shares during the period. FNY Investment Advisers LLC grew its stake in shares of Janux Therapeutics by 6,928.6% in the first quarter. FNY Investment Advisers LLC now owns 2,460 shares of the company's stock valued at $66,000 after buying an additional 2,425 shares in the last quarter. Finally, KBC Group NV acquired a new stake in shares of Janux Therapeutics in the first quarter valued at about $66,000. Institutional investors and hedge funds own 75.39% of the company's stock.

Janux Therapeutics Trading Up 0.8%

Shares of NASDAQ:JANX opened at $23.04 on Thursday. Janux Therapeutics has a twelve month low of $21.97 and a twelve month high of $71.71. The company's 50 day moving average is $24.50 and its 200 day moving average is $26.93. The company has a market cap of $1.38 billion, a PE ratio of -12.80 and a beta of 2.84.

Janux Therapeutics (NASDAQ:JANX - Get Free Report) last released its quarterly earnings data on Thursday, August 7th. The company reported ($0.55) EPS for the quarter, missing the consensus estimate of ($0.48) by ($0.07). Equities research analysts predict that Janux Therapeutics will post -1.38 earnings per share for the current fiscal year.

About Janux Therapeutics

Janux Therapeutics, Inc, a clinical stage biopharmaceutical company, develops immunotherapies based on Tumor Activated T Cell Engagers (TRACTr) and Tumor Activated Immunomodulators (TRACIr) platforms technology to treat patients suffering from cancer. The company's clinical candidates comprise JANX007, a prostate-specific membrane antigen or PSMA-TRACTr, which is in Phase 1 clinical trial in adults for the treatment of metastatic castration-resistant prostate cancer (mCRPC) and the vasculature of other tumors; and JANX008, an epidermal growth factor receptor or EGFR-TRACTr that is in Phase 1 clinical trial for the treatment of multiple solid cancers, including colorectal cancer, squamous cell carcinoma of the head and neck, non-small cell lung cancer, and renal cell carcinoma.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.